Asthma Drugs Market Size, Growth, Demands Outlook and Forecasts to 2030

According to the research report, the global asthmadrugs market size is expected to touch USD 34.28 Billion by 2030, from USD 21.65 Billion in 2021, growing with a significant CAGR of 5.2% from 2022 to 2030.

The asthma drugs market report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global asthma drugs market in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global asthma drugs market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global asthma drugs market during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1225

Scope of the Asthma Drugs Market

Report Highlights	Details
Market Size	USD 34.65 Billion by 2030
Growth Rate	CAGR of 5.2% From 2022 to 2030
Base Year	2021
Historic Data	2017 to 2021
Forecast Period	2022 to 2030
Segments Covered	Medication, Mode of Administration, Source, Organization Type, Application
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

This study covers a detailed segmentation of the global asthma drugs market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global asthma drugs market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

GlaxoSmithKline
Pfizer
Vectura Group
Boehringer Ingelheim
Roche
Novartis
Merck
AstraZeneca
Teva Pharmaceutical

Market Segmentation

By Medication

Quick Relief Medications
Long-term Control Medications
Others

By Mode of Administration

Tablets and Capsules
Liquids
Inhalers
Injections
Sprays and Powders

By Source

Environmental
Generic

By Organization Type

Public
Private

By Application

Pediatric
Adults
Adolescent

By Geography

North America
- - U.S.
  - Canada
Europe
- - Germany
  - France
  - United Kingdom
  - Rest of Europe
Asia Pacific
- - China
  - Japan
  - India
  - Southeast Asia
  - Rest of Asia Pacific
Latin America
- - Brazil
  - Rest of Latin America
Middle East & Africa (MEA)
- - GCC
  - North Africa
  - South Africa
  - Rest of Middle East & Africa

Research Methodology

The research methodology adopted by analysts for compiling the global asthma drugs market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global asthma drugs market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Asthma Drugs Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Asthma Drugs Market

5.1. Covid-19: Asthma Drugs Industry Impact
5.2. Asthma Drugs Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Asthma Drugs Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Asthma Drugs Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Asthma Drugs Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increasing prevalence of asthma, along with increase in ageing population
6.1.1.2. Increase in pipeline products growth in initiatives implemented by the government and non-government associations for rise in health awareness
6.1.2. Market Restraints
6.1.2.1. Stringent government regulatory requirement for the approval of asthma drugs
6.1.3. Market Opportunities
6.1.3.1. Major companies are focusing on broadening their product portfolio

Chapter 7. Global Asthma Drugs Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Asthma Drugs Market Revenue by Market Players (2017 - 2020)
7.1.1.2. Asthma Drugs Market Revenue Market Share by Market Players (2017 - 2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Process Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Asthma Drugs Market, By Medication Type

8.1. Asthma Drugs Market, by Medication Type, 2017-2030
8.1.1. Quick Relief Medications
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Long-term Control Medications
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Asthma Drugs Market, By Mode of Administration

9.1. Asthma Drugs Market, by Mode of Administration, 2017-2030
9.1.1. Tablets and Capsules
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Liquids
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Inhalers
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Injections
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Sprays and Powders
9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Asthma Drugs Market, By Source

10.1. Asthma Drugs Market, by Source, 2017-2030
10.1.1. Environmental
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Generic
10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Asthma Drugs Market, By Organization Type

11.1. Asthma Drugs Market, by Application, 2017-2030
11.1.1. Public
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Private
11.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Asthma Drugs Market, By Application

12.1. Asthma Drugs Market, by Application, 2017-2030
12.1.1. Pediatric
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Adults
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Adolescent
12.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Asthma Drugs Market, Regional Estimates and Trend Forecast

13.1. North America
13.1.1. Market Revenue Forecast by Medication Type (2017-2030)
13.1.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.1.3. Market Revenue Forecast by Source (2017-2030)
13.1.4. Market Revenue Forecast by Organization Type (2017-2030)
13.1.5. Market Revenue Forecast by Application (2017-2030)
13.1.6. U.S
13.1.6.1. Market Revenue Forecast (2017-2030)
13.1.7. Canada
13.1.7.1. Market Revenue Forecast (2017-2030)
13.2. Europe
13.2.1. Market Revenue Forecast by Medication Type (2017-2030)
13.2.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.2.3. Market Revenue Forecast by Source (2017-2030)
13.2.4. Market Revenue Forecast by Organization Type (2017-2030)
13.2.5. Market Revenue Forecast by Application (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue Forecast (2017-2030)
13.2.7. Germany
13.2.7.1. Market Revenue Forecast (2017-2030)
13.2.8. France
13.2.8.1. Market Revenue Forecast (2017-2030)
13.2.9. Rest of EU
13.2.9.1. Market Revenue Forecast (2017-2030)
13.3. Asia Pacific (APAC)
13.3.1. Market Revenue Forecast by Medication Type (2017-2030)
13.3.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.3.3. Market Revenue Forecast by Source (2017-2030)
13.3.4. Market Revenue Forecast by Organization Type (2017-2030)
13.3.5. Market Revenue Forecast by Application (2017-2030)
13.3.6. China
13.3.6.1. Market Revenue Forecast (2017-2030)
13.3.7. India
13.3.7.1. Market Revenue Forecast (2017-2030)
13.3.8. Japan
13.3.8.1. Market Revenue Forecast (2017-2030)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue Forecast (2017-2030)
13.4. LATAM
13.4.1. Market Revenue Forecast by Medication Type (2017-2030)
13.4.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.4.3. Market Revenue Forecast by Source (2017-2030)
13.4.4. Market Revenue Forecast by Organization Type (2017-2030)
13.4.5. Market Revenue Forecast by Application (2017-2030)
13.4.6. Brazil
13.4.6.1. Market Revenue Forecast (2017-2030)
13.4.7. Rest of LATAM
13.4.7.1. Market Revenue Forecast (2017-2030)
13.5. Middle East and Africa (MEA)
13.5.1. Market Revenue Forecast by Medication Type (2017-2030)
13.5.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.5.3. Market Revenue Forecast by Source (2017-2030)
13.5.4. Market Revenue Forecast by Organization Type (2017-2030)
13.5.5. Market Revenue Forecast by Application (2017-2030)
13.5.6. GCC
13.5.6.1. Market Revenue Forecast (2017-2030)
13.5.7. North Africa
13.5.7.1. Market Revenue Forecast (2017-2030)
13.5.8. South Africa
13.5.8.1. Market Revenue Forecast (2017-2030)
13.5.9. Rest of MEA
13.5.9.1. Market Revenue Forecast (2017-2030)

Chapter 14. Company Profiles

14.1. Pfizer
14.1.1. Company Overview, Business Information, Regional Presence
14.1.2. Product Portfolio Analysis
14.1.2.1. Product Details, Specification, Product Type
14.1.3. Revenue, Price, and Gross Margin (2017-2020)
14.1.4. Recent Developments and Strategies
14.2. GlaxoSmithKline
14.2.1. Company Overview, Business Information, Regional Presence
14.2.2. Product Portfolio Analysis
14.2.2.1. Product Details, Specification, Product Type
14.2.3. Revenue, Price, and Gross Margin (2017-2020)
14.2.4. Recent Developments and Strategies
14.3. Novartis
14.3.1. Company Overview, Business Information, Regional Presence
14.3.2. Product Portfolio Analysis
14.3.2.1. Product Details, Specification, Product Type
14.3.3. Revenue, Price, and Gross Margin (2017-2020)
14.3.4. Recent Developments and Strategies
14.4. Merck
14.4.1. Company Overview, Business Information, Regional Presence
14.4.2. Product Portfolio Analysis
14.4.2.1. Product Details, Specification, Product Type
14.4.3. Revenue, Price, and Gross Margin (2017-2020)
14.4.4. Recent Developments and Strategies
14.5. Boehringer Ingelheim
14.5.1. Company Overview, Business Information, Regional Presence
14.5.2. Product Portfolio Analysis
14.5.2.1. Product Details, Specification, Product Type
14.5.3. Revenue, Price, and Gross Margin (2017-2020)
14.5.4. Recent Developments and Strategies
14.6. AstraZeneca
14.6.1. Company Overview, Business Information, Regional Presence
14.6.2. Product Portfolio Analysis
14.6.2.1. Product Details, Specification, Product Type
14.6.3. Revenue, Price, and Gross Margin (2017-2020)
14.6.4. Recent Developments and Strategies
14.7. Roche
14.7.1. Company Overview, Business Information, Regional Presence
14.7.2. Product Portfolio Analysis
14.7.2.1. Product Details, Specification, Product Type
14.7.3. Revenue, Price, and Gross Margin (2017-2020)
14.7.4. Recent Developments and Strategies
14.8. Teva Pharmaceutical
14.8.1. Company Overview, Business Information, Regional Presence
14.8.2. Product Portfolio Analysis
14.8.2.1. Product Details, Specification, Product Type
14.8.3. Revenue, Price, and Gross Margin (2017-2020)
14.8.4. Recent Developments and Strategies
14.9. Vectura Group
14.9.1. Company Overview, Business Information, Regional Presence
14.9.2. Product Portfolio Analysis
14.9.2.1. Product Details, Specification, Product Type
14.9.3. Revenue, Price, and Gross Margin (2017-2020)
14.9.4. Recent Developments and Strategies